Semaglutide
Established GLP-1 receptor agonist mimicking natural incretin hormones with modified clearance curves.
Open Semaglutide in the 3D analyzerAnalytical specification
| Empirical formula | C187H291N45O59 |
|---|---|
| Molecular weight | 4113.6 g/mol |
| Isoelectric point (pI) | 5.45 |
| Assay purity (HPLC) | 99.50% |
| Retention time | 6.20 min |
| Peak area / height | 14780 / 1180 |
| Reference batch | SE-2026-A10 |
| Research category | Metabolic & Weight Management |
| Amino-acid sequence | H-Aib-E-G-T-F-T-S-D-V-S-S-Y-L-E-G-Q-A-A-K-E-F-I-A-W-L-V-R-G-R-G |
Research characteristics
GLP-1 Mimicry
94% structural alignment with native human GLP-1
Appetite Control
Direct central nervous satiety signaling
Cardiovascular Benefit
Promotes favorable vascular safety profiles
Pancreatic Aid
Fosters beta-cell preservation parameters
Reconstitution
Use the interactive reconstitution calculator to convert vial size (mg), bacteriostatic water volume (ml) and target dose (mcg) into a syringe draw on a standard 100-unit insulin syringe. Open the dosage calculator.
Related metabolic & weight management compounds
Retatrutide (Reta)
Next-generation triple receptor agonist (GLP-1, GIP, GCGR) driving advanced metabolic homeostasis.
Tirzepatide (Tirze)
Dual GIP and GLP-1 receptor agonist targeting glucose homeostasis and body composition dynamics.
Liraglutide
Acylated human glucagon-like peptide-1 analog designed for clinical metabolic investigation models.
Cagrilintide
Long-acting amylin analogue targeting dual pathways in conjunction with incretin receptor systems.
Mazdutide
Novel dual GLP-1R/GCGR agonist targeting lipid elimination and cellular thermodynamic burn.
Orforglipron
Non-peptide oral small-molecule GLP-1 receptor agonist engineered for high bio-availability trials.